Tony Hagen

If it has strong intentions to develop the IL-23 agent brazikumab for commercialization, AstraZeneca did not show its hand when it acknowledged receipt of the agent from Allergan last week.

As it emerges from organizational restructuring, Outlook Therapeutics expresses confidence in its bevacizumab candidate for retinal diseases.

In a trio of studies, investigators were able to demonstrate equivalency of Samsung Bioepis’ trastuzumab biosimilar in various settings.

Icelandic company Alvotech said clinical trials for its adalimumab candidate have demonstrated equivalence to reference product Humira.

Celltrion is pinning its hopes on a higher-concentration formulation of adalimumab to gain elbow room among multiple competing products.

Australia’s secretive drug approval system gives what some believe is an unfair advantage to rival drug companies.

With successful findings from a phase 3 trial of its bevacizumab biosimilar candidate, Iranian company AryoGen Pharmed is a step closer to commercialization of this product.

A retrospective study of physician surveys on biosimilars demonstrated that understanding physician attitudes toward biosimilars is crucial to improving uptake of these agents.

The Federal Trade Commission was deeply divided over whether the AbbVie-Allergan $63 billion merger plan would allow for a sufficiently competitive marketplace.

Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.

After 17 years on the US market, Humira (adalimumab) proves it can still generate high sales, but competition from biosimilars is growing.

Trying to carve back its market share for Neupogen, its filgrastim originator product, Amgen is hoping product exclusivity can be backdated.

Pfizer is battling biosimilar competition as its brands lose exclusivity but it is fighting fire with fire, launching multiple biosimilars of its own. Biogen has extended its commercialization agreements for biosimilars and said its earnings picture improved in the first quarter of 2020.

Taking an abundance of time to file a motion to block Kanjinti from coming to market, Genentech unwittingly may have tipped the scales in favor of biosimilar applicants.

Henlius Biotech said its manufacturing facility has met European standards for production of its trastuzumab biosimilar candidate, which the company said is "a passport" for potential commericialization across the globe.

A New Zealand study of patients with rheumatic conditions suggests that providers need to be mindful of patient attitudes toward biosimilars to prevent biased therapy choices and poor outcomes.

Samsung Bioepis isn't flinching on its trastuzumab biosimilar launch schedule, COVID-19 and 4 other biosimilar competitors notwithstanding, said Sang-Jin Pak, MD, executive vice president of the company's Commercial Division.

Jeenal Patel, PharmD, BCGP, a formulary manager for WellDyne, said pharmacy benefit managers (PBMs) and employers are increasingly turning to formulary exclusions to control the rising cost of drugs.

Many additional biosimilars could be on the market by 2025, said presenters at the Academy of Managed Care Pharmacy eLearning Days virtual meeting.

A Swedish company that wants to bring a ranibizumab biosimilar to market said it may finish trial enrollment despite the pandemic.

In partnership with Samsung Bioepis, Merck has launched the trastuzumab biosimilar Ontruzant, which marks the fifth trastuzumab biosimilar available on the US market.

The first 3 months of 2019 saw a trio of biosimilar launches on the US market, ahead of the year-ago quarter's pace, and this came despite the disruption caused by coronavirus disease 2019.

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

With positive phase 1 study results and a manufacturing process that may cut costs significantly, BiosanaPharma hopes its omalizumab biosimilar candidate will have an edge on the worldwide market.

The FDA’s new focus on coronavirus disease 2019 (COVID-19) and the quarantines imposed on much of the developed world have pushed digital and remote marketing of pharmaceutical products into high gear, according to Jamie Peck, managing director of iON.

Longtime generics manufacturer Lannett is moving an insulin glargine biosimilar development plan forward and announced an upcoming meeting with the FDA. The agent would compete with the reference product Lantus.

Trade groups and consumer advocates are working to fight the rising tide of protectionism generated by the coronavirus disease 2019 pandemic. The International Generic and Biosimilar Medicines Association (IGBA) is calling for dedicated air and sea channels to keep pipelines of essential medicines open between borders.

The race to find a way to knock down the coronavirus disease 2019 pandemic has attracted companies with stakes in the biosimilar game. The winner could take all.

After a number of issues raised by the FDA about plant quality, Biocon has gotten clearance for its Malaysia insulin plant and now awaits FDA marketing authorization for Semglee, its insulin glargine agent.

Canadian provinces encounter opposition in their move to implement forced switching of patients from reference products to biosimilars.